Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Staff Appointments Bring Ties To HELP Committee, Sen. Baucus

This article was originally published in The Tan Sheet

Executive Summary

Top staff members recently added at the Department of Health and Human Services bring ties to key health policy figures or Senate committees

You may also be interested in...



Daschle’s Exit Cedes Control Of Health Care Reform To Baucus, Waxman

The Obama administration's formula for making comprehensive health care reform work in 2009 was straightforward: have an experienced team in place in all of the relevant health and budget areas immediately; prepare a manageable piece of legislation for early in the first year; and rely on the political clout of the perfect political general to keep Congress focused and in line

HHS Deputy Corr May Reignite FDA Tobacco Oversight; PhRMA Sees Upside

Health and Human Services Secretary-designate Tom Daschle's pick of William Corr as deputy secretary will be a key policy appointment should the Obama administration decide to make FDA regulation of tobacco a priority for the next congressional session

Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs

The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel